Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy

Figure 2

Schematic presentation of the electrochemiluminescent bridging immunoassay. Patient samples were diluted at the minimum required dilution, mixed with biotin- and ruthenium-conjugated test drug (lipegfilgrastim or pegfilgrastim) and the complex formed by antidrug antibodies (ADA). The drug conjugates were captured on a streptavidin-coated assay plate. In the presence of a read buffer containing tripropylamine and upon application of an electrical potential, the ruthenium tag emits light.